New cancer indication for Kymriah

Novartis has received a new cancer indication for its chimeric antigen receptor T (CAR-T) cell therapy Kymriah (tisagenlecleucel) enabling the gene therapy to be administered to a broader group of patients. The new indication is for large B cell lymphoma, including diffuse large B cell lymphoma (DLBCL).

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland